论文部分内容阅读
病毒唑静脉用药可造成对血液系统的损伤已被证实,但用药多久其毒副作用方可发生;选择非静脉给药途径能否避免其对血液系统不利影响,同时又不降低其抗病毒效果。目前国内研究较少。为此我们采用病毒唑雾化吸入治疗喘憋性肺炎,并与静脉用药比较,观察两组用药疗效及用药前后末梢血象变化。结果表明,雾化给药组无论在止咳、平喘、肺部罗音和 X 线炎症吸收效果均明显优于静脉用药组(P<0.01),其住院时间明显缩短;雾化给药不但对血液系统无不良影响,而且还有助于红细胞、血红蛋白恢复正常;病毒唑(20mg/kg·d)静脉用药1周无造成对血液系统不利影响之虑,但其临床疗效明显逊色于雾化途径用药。提示病毒唑雾化吸入用于治疗呼吸道病毒感染完全可以取代静脉途径用药,且疗效可靠,并可避免长期静脉用药所引起的毒副作用。
The administration of ribavirin can cause damage to the blood system has been confirmed, but how long the drug side effects can occur; choice of non-intravenous route of administration can avoid adverse effects on the blood system, without reducing its antiviral effect. At present, less research in China. To this end, we use inhalation of ribavirin aerosol asthma pneumonia, and compared with intravenous administration, the two groups observed the efficacy of treatment and before and after treatment peripheral blood changes. The results showed that both the cough, asthma, lung rales and X-ray inflammation absorption effect of the atomized group were significantly better than that of the intravenous group (P <0.01), and the hospitalization time was significantly shortened; Blood system without adverse effects, but also help to red blood cells, hemoglobin returned to normal; ribavirin (20mg / kg · d) for 1 week did not cause adverse effects on the blood system, but its clinical efficacy significantly less than the atomization pathway Medication. These results suggest that inhalation of ribavirin for the treatment of respiratory virus infection can completely replace the intravenous route of medication, and the curative effect is reliable, and can avoid long-term intravenous drug-induced side effects.